MX2020007606A - Terapia de combinacion contra cd70. - Google Patents

Terapia de combinacion contra cd70.

Info

Publication number
MX2020007606A
MX2020007606A MX2020007606A MX2020007606A MX2020007606A MX 2020007606 A MX2020007606 A MX 2020007606A MX 2020007606 A MX2020007606 A MX 2020007606A MX 2020007606 A MX2020007606 A MX 2020007606A MX 2020007606 A MX2020007606 A MX 2020007606A
Authority
MX
Mexico
Prior art keywords
binds
combination therapy
stem cell
antibody molecule
malignancy
Prior art date
Application number
MX2020007606A
Other languages
English (en)
Inventor
Rompaey Luc Van
Mahan Moshir
Piotr Zabrocki
Tim Delahaye
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of MX2020007606A publication Critical patent/MX2020007606A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a terapias de combinación para el tratamiento de neoplasia, particularmente de la neoplasia mieloide tal como leucemia mieloide aguda (AML). Las terapias de combinación pueden incluir una molécula de anticuerpo que se une a CD70 y al menos una molécula de anticuerpo que se une a un blanco de células madre leucémicas. Los blancos de células madre leucémicas preferidos son TIM-3, IL1 R3/IL1 RAP y CD47.
MX2020007606A 2018-01-16 2019-01-16 Terapia de combinacion contra cd70. MX2020007606A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1800649.4A GB201800649D0 (en) 2018-01-16 2018-01-16 CD70 Combination Therapy
PCT/EP2019/051058 WO2019141732A1 (en) 2018-01-16 2019-01-16 Cd70 combination therapy

Publications (1)

Publication Number Publication Date
MX2020007606A true MX2020007606A (es) 2020-09-03

Family

ID=61256176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007606A MX2020007606A (es) 2018-01-16 2019-01-16 Terapia de combinacion contra cd70.

Country Status (22)

Country Link
US (2) US11530271B2 (es)
EP (2) EP4275702A3 (es)
JP (2) JP7511479B2 (es)
KR (1) KR102790232B1 (es)
CN (1) CN111836830B (es)
AU (1) AU2019209503B2 (es)
BR (1) BR112020014321A2 (es)
CA (1) CA3086448A1 (es)
DK (1) DK3740504T5 (es)
EA (1) EA202091714A1 (es)
ES (1) ES2956258T3 (es)
FI (1) FI3740504T3 (es)
GB (1) GB201800649D0 (es)
HU (1) HUE063783T2 (es)
IL (1) IL276103A (es)
LT (1) LT3740504T (es)
MX (1) MX2020007606A (es)
PL (1) PL3740504T3 (es)
PT (1) PT3740504T (es)
SG (1) SG11202006007YA (es)
WO (1) WO2019141732A1 (es)
ZA (1) ZA202003986B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180293B2 (en) 2018-01-16 2024-12-31 argenx BV CD70 combination therapy

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
JP2022548627A (ja) * 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
EP4090335A1 (en) * 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021226289A2 (en) * 2020-05-05 2021-11-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とｃｄ４７遮断の併用
CN114765061B (zh) * 2021-01-15 2024-12-27 深圳哲源生物科技有限责任公司 Pd-1/pd-l1抑制剂的不良预后的数据处理系统及方法
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
US20240165229A1 (en) * 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
NZ533240A (en) 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
EA015706B1 (ru) 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
AU2008324203A1 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010019921A2 (en) 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
ES2835553T3 (es) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
WO2011035433A1 (en) 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
MX2012005791A (es) 2009-11-19 2012-07-03 Merck Serono Sa Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.
AU2010339359A1 (en) 2009-12-29 2012-07-26 Kyowa Hakko Kirin Co., Ltd. Anti-CD27 antibody
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
AP2014007588A0 (en) 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
JO3787B1 (ar) 2012-03-15 2021-01-31 Janssen Biotech Inc أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
RU2627712C2 (ru) 2012-06-15 2017-08-10 Кьюрдженикс Инк. Соединение как ингибитор передачи сигналов wnt, его композиции и применение
AU2013310924B2 (en) 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150315279A1 (en) 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US20220136068A1 (en) 2019-03-06 2022-05-05 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
MX2023002318A (es) 2020-08-29 2023-05-19 argenx BV Metodo de tratamiento de pacientes con sensibilidad reducida a un inhibidor de bcl-2.
AU2021358768A1 (en) 2020-10-06 2023-05-18 The Regents Of The University Of Colorado, A Body Corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180293B2 (en) 2018-01-16 2024-12-31 argenx BV CD70 combination therapy

Also Published As

Publication number Publication date
CN111836830B (zh) 2024-08-23
EP4275702A2 (en) 2023-11-15
JP2021510736A (ja) 2021-04-30
US20240002523A1 (en) 2024-01-04
EP4275702A3 (en) 2024-02-28
IL276103A (en) 2020-08-31
LT3740504T (lt) 2023-09-11
AU2019209503A1 (en) 2020-07-09
WO2019141732A1 (en) 2019-07-25
GB201800649D0 (en) 2018-02-28
HUE063783T2 (hu) 2024-01-28
BR112020014321A2 (pt) 2020-12-08
EP3740504B1 (en) 2023-07-19
EP3740504B9 (en) 2023-11-22
FI3740504T3 (fi) 2023-10-11
US12180293B2 (en) 2024-12-31
EP3740504A1 (en) 2020-11-25
DK3740504T3 (da) 2023-10-23
ES2956258T3 (es) 2023-12-18
US11530271B2 (en) 2022-12-20
KR20200110658A (ko) 2020-09-24
SG11202006007YA (en) 2020-08-28
ZA202003986B (en) 2025-04-30
PL3740504T3 (pl) 2024-01-29
EA202091714A1 (ru) 2020-10-15
JP2024037765A (ja) 2024-03-19
DK3740504T5 (da) 2024-07-15
CA3086448A1 (en) 2019-07-25
AU2019209503B2 (en) 2025-08-28
JP7511479B2 (ja) 2024-07-05
WO2019141732A9 (en) 2020-05-22
PT3740504T (pt) 2023-10-04
US20190241668A1 (en) 2019-08-08
KR102790232B1 (ko) 2025-04-03
CN111836830A (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
ZA202003986B (en) Cd70 combination therapy
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
GEP20257822B (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2020010444A (es) Complejos de péptidos bicíclicos en heterotándem.
MX2023013912A (es) Metodos para inhibir ras.
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
CY1121813T1 (el) Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
ZA201905051B (en) Anti-pd-1 antibodies for treatment of lung cancer
NZ737418A (en) Anti-ntb-a antibodies and related compositions and methods
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
PE20211860A1 (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
BR112012021941A2 (pt) Proteínas terapêuticas de ligação a dll4
AU2018278730A1 (en) A novel anti-c-Met antibody and use thereof
AU2017269839A1 (en) Methods for treatment of refractory generalized myasthenia gravis
WO2021133653A8 (en) Therapy for the treatment of cancer
BR112019004185A2 (pt) combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
WO2019224385A3 (en) Combined bispecific antibody and immuno-oncology therapies
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
MX2021000043A (es) Activadores de la respuesta a proteinas desplegadas.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
WO2022115565A3 (en) Chimeric receptors and methods of use thereof